Cross-reactive single-domain antibodies to hemagglutinin stem region protect mice from group 1 influenza A virus infection

• Published in: bioRxiv 2022-09
• Main Authors: Voronina, Darya V, Bandelyuk, Alina S, Alina Sh Dzharullaeva, Popova, Olga, Vladislav Yu Kan, Esmagambetov, Ilias B, Favorskaya, Irina A, Shcheblyakov, Dmitry V, Naroditskiy, Boris S, Gintsburg, Aleksandr L
• Format: Article
• Language: English
• Subjects: Antibodies; Antiviral activity; Antiviral agents; Disease prevention; Hemagglutinins; Infections; Influenza; Influenza A; Nanobodies; Orthomyxoviridae; Prophylaxis; Vaccination; Viruses
• DOI: 10.1101/2022.09.29.510074

The continued evolution of influenza viruses reduces the effectiveness of vaccination and antiviral drugs. The identification of novel and universal agents for influenza prophylaxis and treatment is an urgent need. We have previously described two potent single-domain antibodies (VHH), G2.3 and H1.2, which efficiently neutralize H1N1 and H5N2 influenza viruses in vivo. In this study, we modified these VHHs with Fc-fragment to enhance their antiviral activity. Reformatting of G2.3 into bivalent Fc-fusion molecule increased its in vitro neutralizing activity against H1N1 and H2N3 viruses up to 20-fold and, moreover, resulted in obtaining the ability to neutralize H5N2 and H9N2 subtypes. We demonstrated that a dose as low as 0.6 mg/kg of G2.3-Fc or H1.2-Fc administered systemically or locally before infection could protect mice from lethal challenges with both H1N1 and H5N2 viruses. Furthermore, G2.3-Fc reduced the lung viral load to an undetectable level. Both VHH-Fc showed in vivo therapeutic efficacy when delivered via systemic or local route. The findings support G2.3-Fc as a potential therapeutic agent for both prophylaxis and therapy of Group 1 influenza A infection. Competing Interest Statement The authors have declared no competing interest.